Compare EVTV & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTV | EVAX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 42.7M |
| IPO Year | 2017 | 2021 |
| Metric | EVTV | EVAX |
|---|---|---|
| Price | $0.45 | $4.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.33 |
| AVG Volume (30 Days) | ★ 2.1M | 107.1K |
| Earning Date | 11-20-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,696,856.00 | ★ $7,650,000.00 |
| Revenue This Year | N/A | $128.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 113.69 | ★ 132.17 |
| 52 Week Low | $0.40 | $1.20 |
| 52 Week High | $14.00 | $12.15 |
| Indicator | EVTV | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 22.09 | 40.15 |
| Support Level | $0.40 | $4.60 |
| Resistance Level | $0.52 | $6.70 |
| Average True Range (ATR) | 0.14 | 0.54 |
| MACD | -0.07 | -0.13 |
| Stochastic Oscillator | 4.91 | 5.71 |
Envirotech Vehicles Inc is a provider of purpose-built zero-emission electric vehicles focused on reducing the total cost of vehicle ownership and helping fleet operators unlock the benefits of green technology. It recognizes revenue from the sales of zero-emission electric vehicles and vehicle maintenance and inspection services. The Company serves commercial and last-mile fleets, school districts, public and private transportation service companies and colleges and universities to meet the increasing demand for light to heavy-duty electric vehicles.
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.